Hancock Jaffe Laboratories (NASDAQ: HJLI) is one of 124 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare Hancock Jaffe Laboratories to similar businesses based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, risk and valuation.
This is a summary of current ratings and target prices for Hancock Jaffe Laboratories and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Hancock Jaffe Laboratories||0||0||0||0||N/A|
|Hancock Jaffe Laboratories Competitors||876||2974||5137||260||2.52|
Institutional and Insider Ownership
1.1% of Hancock Jaffe Laboratories shares are held by institutional investors. Comparatively, 51.4% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.2% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Hancock Jaffe Laboratories and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Hancock Jaffe Laboratories||$190,000.00||-$13.04 million||-0.60|
|Hancock Jaffe Laboratories Competitors||$1.47 billion||$148.12 million||51.93|
Hancock Jaffe Laboratories’ peers have higher revenue and earnings than Hancock Jaffe Laboratories. Hancock Jaffe Laboratories is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Hancock Jaffe Laboratories and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Hancock Jaffe Laboratories||-5,161.19%||-302.90%||-182.37%|
|Hancock Jaffe Laboratories Competitors||-788.03%||-109.14%||-21.96%|
Hancock Jaffe Laboratories peers beat Hancock Jaffe Laboratories on 9 of the 9 factors compared.
About Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.